THROMB RES 润色咨询

THROMBOSIS RESEARCH

出版年份:暂无数据 年文章数:1987 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:5.9% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0<br>经验分享:4月16号投稿,5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0<br>经验分享:2021.08.01投的,2021.09.03就是All Reviews Completed,到现在也没结果,还在编辑手里,前两天发了催稿信,但是回复的都是套话,急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗? 冠心病血瘀证 多组学筛选后做了一些血小板自噬 蛋白的验证,文章不是很深刻,有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:审稿一周,<br>返修后再审一周,<br>校样一周,<br>效率很高,很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=376, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享:投过两篇,中了两篇,很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578625, encodeId=3ebd5e862537, content=审稿时间有点长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:血栓;基础研究<br>经验分享:不难投稿,但是今年影响因子估计掉的很厉害!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2022-05-29 ms9000001396467020

    审稿速度:2.0
    经验分享:4月16号投稿,5月29日仍然是under review是正常的吗

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0<br>经验分享:4月16号投稿,5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0<br>经验分享:2021.08.01投的,2021.09.03就是All Reviews Completed,到现在也没结果,还在编辑手里,前两天发了催稿信,但是回复的都是套话,急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗? 冠心病血瘀证 多组学筛选后做了一些血小板自噬 蛋白的验证,文章不是很深刻,有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:审稿一周,<br>返修后再审一周,<br>校样一周,<br>效率很高,很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=376, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享:投过两篇,中了两篇,很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578625, encodeId=3ebd5e862537, content=审稿时间有点长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:血栓;基础研究<br>经验分享:不难投稿,但是今年影响因子估计掉的很厉害!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2021-10-07 ms3000001155211603

    审稿速度:3.0
    经验分享:2021.08.01投的,2021.09.03就是All Reviews Completed,到现在也没结果,还在编辑手里,前两天发了催稿信,但是回复的都是套话,急着毕业啊~难受

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0<br>经验分享:4月16号投稿,5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0<br>经验分享:2021.08.01投的,2021.09.03就是All Reviews Completed,到现在也没结果,还在编辑手里,前两天发了催稿信,但是回复的都是套话,急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗? 冠心病血瘀证 多组学筛选后做了一些血小板自噬 蛋白的验证,文章不是很深刻,有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:审稿一周,<br>返修后再审一周,<br>校样一周,<br>效率很高,很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=376, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享:投过两篇,中了两篇,很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578625, encodeId=3ebd5e862537, content=审稿时间有点长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:血栓;基础研究<br>经验分享:不难投稿,但是今年影响因子估计掉的很厉害!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2023-07-28 1378327198@qq.com 来自湖南省

    请问这个杂志收中医学基础研究的文章吗? 冠心病血瘀证 多组学筛选后做了一些血小板自噬 蛋白的验证,文章不是很深刻,有没有可能投中啊。有没有希望🤣🤣

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0<br>经验分享:4月16号投稿,5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0<br>经验分享:2021.08.01投的,2021.09.03就是All Reviews Completed,到现在也没结果,还在编辑手里,前两天发了催稿信,但是回复的都是套话,急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗? 冠心病血瘀证 多组学筛选后做了一些血小板自噬 蛋白的验证,文章不是很深刻,有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:审稿一周,<br>返修后再审一周,<br>校样一周,<br>效率很高,很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=376, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享:投过两篇,中了两篇,很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578625, encodeId=3ebd5e862537, content=审稿时间有点长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:血栓;基础研究<br>经验分享:不难投稿,但是今年影响因子估计掉的很厉害!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2022-03-31 wangzzzzzzz

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享:审稿一周,
    返修后再审一周,
    校样一周,
    效率很高,很友好

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0<br>经验分享:4月16号投稿,5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0<br>经验分享:2021.08.01投的,2021.09.03就是All Reviews Completed,到现在也没结果,还在编辑手里,前两天发了催稿信,但是回复的都是套话,急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗? 冠心病血瘀证 多组学筛选后做了一些血小板自噬 蛋白的验证,文章不是很深刻,有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:审稿一周,<br>返修后再审一周,<br>校样一周,<br>效率很高,很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=376, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享:投过两篇,中了两篇,很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578625, encodeId=3ebd5e862537, content=审稿时间有点长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:血栓;基础研究<br>经验分享:不难投稿,但是今年影响因子估计掉的很厉害!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2018-06-28 m201776035_66684584

    请问这个是需要所有作者都注册杂志账号才能投稿吗?

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0<br>经验分享:4月16号投稿,5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0<br>经验分享:2021.08.01投的,2021.09.03就是All Reviews Completed,到现在也没结果,还在编辑手里,前两天发了催稿信,但是回复的都是套话,急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗? 冠心病血瘀证 多组学筛选后做了一些血小板自噬 蛋白的验证,文章不是很深刻,有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:审稿一周,<br>返修后再审一周,<br>校样一周,<br>效率很高,很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=376, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享:投过两篇,中了两篇,很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578625, encodeId=3ebd5e862537, content=审稿时间有点长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:血栓;基础研究<br>经验分享:不难投稿,但是今年影响因子估计掉的很厉害!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2018-09-22 1321f1834cm

    审稿速度:2.0 | 投稿命中率:95.0
    经验分享:投过两篇,中了两篇,很友好的杂志。

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0<br>经验分享:4月16号投稿,5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0<br>经验分享:2021.08.01投的,2021.09.03就是All Reviews Completed,到现在也没结果,还在编辑手里,前两天发了催稿信,但是回复的都是套话,急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗? 冠心病血瘀证 多组学筛选后做了一些血小板自噬 蛋白的验证,文章不是很深刻,有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:审稿一周,<br>返修后再审一周,<br>校样一周,<br>效率很高,很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=376, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享:投过两篇,中了两篇,很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578625, encodeId=3ebd5e862537, content=审稿时间有点长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:血栓;基础研究<br>经验分享:不难投稿,但是今年影响因子估计掉的很厉害!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2019-10-25 147612bem32暂无昵称

    审稿时间有点长

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0<br>经验分享:4月16号投稿,5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0<br>经验分享:2021.08.01投的,2021.09.03就是All Reviews Completed,到现在也没结果,还在编辑手里,前两天发了催稿信,但是回复的都是套话,急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗? 冠心病血瘀证 多组学筛选后做了一些血小板自噬 蛋白的验证,文章不是很深刻,有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:审稿一周,<br>返修后再审一周,<br>校样一周,<br>效率很高,很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=376, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享:投过两篇,中了两篇,很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578625, encodeId=3ebd5e862537, content=审稿时间有点长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:血栓;基础研究<br>经验分享:不难投稿,但是今年影响因子估计掉的很厉害!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2023-02-14 ms4000002125344456 来自上海

    请问网药哪些期刊友好呢?

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0<br>经验分享:4月16号投稿,5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0<br>经验分享:2021.08.01投的,2021.09.03就是All Reviews Completed,到现在也没结果,还在编辑手里,前两天发了催稿信,但是回复的都是套话,急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗? 冠心病血瘀证 多组学筛选后做了一些血小板自噬 蛋白的验证,文章不是很深刻,有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:审稿一周,<br>返修后再审一周,<br>校样一周,<br>效率很高,很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=376, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享:投过两篇,中了两篇,很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578625, encodeId=3ebd5e862537, content=审稿时间有点长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:血栓;基础研究<br>经验分享:不难投稿,但是今年影响因子估计掉的很厉害!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2022-11-03 ms8000001235082561

    请问met a分析这个期刊接收嘛?

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0<br>经验分享:4月16号投稿,5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0<br>经验分享:2021.08.01投的,2021.09.03就是All Reviews Completed,到现在也没结果,还在编辑手里,前两天发了催稿信,但是回复的都是套话,急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗? 冠心病血瘀证 多组学筛选后做了一些血小板自噬 蛋白的验证,文章不是很深刻,有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:审稿一周,<br>返修后再审一周,<br>校样一周,<br>效率很高,很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=376, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享:投过两篇,中了两篇,很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578625, encodeId=3ebd5e862537, content=审稿时间有点长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:血栓;基础研究<br>经验分享:不难投稿,但是今年影响因子估计掉的很厉害!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2022-09-15 ms3000000928163054

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:血栓;基础研究
    经验分享:不难投稿,但是今年影响因子估计掉的很厉害!

    0

共42条页码: 1/5页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分